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Supplementary information  
Supplemental Methods 
Human samples 
Primary human (ph) ATII cells were isolated from non-IPF (N=4) or IPF (N=4) lung tissue 
biopsies from the Comprehensive Pneumology Center cohort of the BioArchive CPC-M at 
the University Hospital Grosshadern of the Ludwig Maximilian University. Participants 
provided written informed consent to participate in this study, in accordance with approval by 
the local ethics committee of the LMU, Germany (Project 333-10, 455-12). Additionally, 
formalin-fixed, paraffin-embedded lung tissue samples from 14 patients with sporadic IPF 
(mean age  sd: 55.82  9.74 years; 5 females, 9 males) and 5 non-diseased control 
subjects (organ donors; mean age  sd: 56.60  11.46 years; 4 females, 1 male) were 
immunohistochemically investigated. All lung tissue samples were collected in frame of the 
European IPF registry (eurIPFreg) and provided by the UGMLC Giessen Biobank (member 
of the DZL Platform Biobanking). The study protocol was approved by the Ethics Committee 
of the Justus-Liebig-University Giessen (No. 111/08 and 58/15). 
Animal experiments 
Six- to eight-week-old pathogen-free female C57BL/6N mice were obtained from Charles 
River and housed in rooms with constant humidity and temperature with 12h light cycles and 
free access to water and rodent chow. For the induction of experimental fibrosis, mice were 
subjected to intratracheal bleomycin (Bleomycin sulfate, Almirall, Barcelona, Spain, was 
dissolved in sterile PBS) instillation using the Micro-Sprayer Aerosolizer, Model IA-1C (Penn-
Century, Wyndmoor, PA), as a single dose of 2 U/kg body weight in 50 µl PBS. Control mice 
were treated with 50 µl PBS. Mice were sacrificed at day 7, 14 or day 21 after instillation. 
Lungs were used for collection of whole lung tissue, ATII cells or 3D-LTCs. All animal studies 
were conducted under strict governmental and international guidelines and approved by the 
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local government for the administrative region of Upper Bavaria (Project 55.2-1-54-2532-88-
12). 
 
Isolation of primary murine alveolar epithelial cell type II (pmATII) cells  
The pmATII cells were isolated from pathogen-free C57BL/6 mice treated with 
PBS/Bleomycin and sacrificed at day 14 after instillation as previously described [1, 2] with 
slight modifications. In brief, lungs were filled with dispase (BD Bioscience, San Jose, CA, 
US) and low gelling temperature agarose (Sigma Aldrich, Saint Louis, MO, USA) before 
tissue was minced and the cell suspension was filtered through 100-, 20-, and 10- m nylon 
meshes (Sefar, Heiden, Switzerland). Negative selection of fibroblasts was performed by 
adherence on non-coated plastic plates. Macrophages and white blood cells were depleted 
with CD45 and endothelial cells were depleted with CD31 specific magnetic beads (Miltenyi 
purity was assessed routinely by analysis of endothelial (CD31), mesenchymal ( -SMA, 
CD90), epithelial (EpCAM, panCK and proSP-C), and hematopoietic cell (CD45) markers by 
immunofluorescence or flow cytometry.  
Isolation of primary human alveolar epithelial type II (phATII) cells 
Isolation of phATII cells was performed as previously described [1, 3], with some 
modifications. Briefly, lung tissue was minced and digested with dispase/collagenase 
(Roche, Basel, Switzerland) at 37°C for 2 h before filtering through nylon meshes and 
centrifugation at 400 g, 4°C for 10 min. Next, the cells were layered onto a discontinuous 
Percoll density gradient (1.04 1.09 g/ml) and centrifuged at 300 g for 20 min. The interphase 
containing macrophages and alveolar epithelial cells was recovered. Macrophages and white 
blood cells were depleted with CD45 specific magnetic beads (Miltenyi Biotec, Bergisch) 
according to the manu  
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Cell culture 
In experiments using pmATII cells were seeded, cultured for 48h, then treated with senolytic 
agents Dasatinib (500 nM, Selleck Chemicals, Houston, TX, USA) and Quercetin (50 µM, 
Sigma Aldrich, St Louis, MO, USA) or respective DMSO control for 24 or 48 h in DMEM 
(Sigma Aldrich) containing 10% FCS (PAA Laboratories, Pasching, Austria), 2 mM l-
glutamine,  (both Life Technologies, 
Carlsbad, CA), 3.6 mg/ml glucose (Applichem GmbH, Darmstadt, Germany) and 10 mM 
HEPES (PAA Laboratories). Senolytic treatment with ABT263 (10 µM, Cayman Chemical, 
Ann Arbor, MI) led to similar results (data not shown). Cells were counted 48 h after 
treatment with a Neubauer counting chamber. RNA was isolated isolated and reverse 
transcribed as described previously [2] and fibrotic gene expression was measured by 
quantitative (q) RT-PCR. Supernatants were collected, centrifuged at 14000 g for 10 min and 
stored at -80°C before analysis. 
RNA isolation and Reverse Transcription Polymerase Chain Reaction (RT-PCR, qPCR) 
Total RNA was extracted using the miRNeasy Mini kit (Qiagen, Hilden, Germany) for human 
tissue and Peqlab Total RNA extraction Kit (Peqlab, Erlangen, Germany) for mouse samples, 
according to t
using SuperScriptTM II (Invitrogen, Carlsbad, CA, USA) and for human tissue with iScript 
Advanced kit (BioRad, Hercules, CA, USA). Quantitative (q)RT-PCR was performed using 
Light Cycler 480 detection system and SYBR Green (Roche Diagnostics, Mannheim, 
Germany). Hypoxanthine phosphoribosyltransferase (HPRT) was used as a reference gene.  
Relative gene expression is presented as Ct value ( Ct =[Ct Hprt]-[Ct gene of interest]). 
Relative change in transcript level upon treatment is expressed as fold change 2^ Ct value 
( Ct= Ct of treated sample- Ct of control).  
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Primers for Col1a1, Fibronectin, Sftpc, Sftpa, T1a, Cdh1 and MMP12 were as previously 
reported with HPRT as reference gene [2, 4]. Additional primers were 
Gene  forward primer reverse primer 
hp16 ACCAGAGGCAGTAACCATGC CCTGTAGGACCTTCGGTGAC 
hp21 GTCAGTTCCTTGTGGAGCCG TGGGTTCTGACGGACATCCC 
mp16 CGGGGACATCAAGACATCGT GCCGGATTTAGCTCTGCTCT 
mp21 ACATCTCAGGGCCGAAAACG AAGACACACAGAGTGAGGGC 
mSpp1 AGCCAAGGACTAACTACGACC TGGCTATAGGATCTGGGTGC 
mMMP2 ATCCACGGTTTCAGGGTCC ATCGAGACCATGCGGAAGC 
mPai1 AGGTCAGGATCGAGGTAAACGAG GGATCGGTCTATAACCATCTCCGT 
mCol5a3 CCACCACTGTCACGATTGGA GAGTCGTCTGCTCGGTTTCAG 
mWisp1 GTCCTGAGGGTGGGCAACAT GGGCGTGTAGTCGTTTCCTCT 
 
Generation and treatment of 3D-LTCs 
C57BL6/N mice of 8-12 weeks were instilled with 2 U/kg bleomycin and sacrificed at day 14 
after instillation. 3D-LTCs were generated as previously described [4]. Briefly, lungs were 
flushed through the heart with sterile sodium chloride solution and filled with low gelling 
supplemented with 100 
Aldrich). Next, lobes were cut with a vibratome (Hyrax V55; Zeiss, Jena, Germany) to a 
thickness of 300 m (speed 10 12 de of 1 mm). 3D-LTCs 
were treated with senolytic agents Dasatinib (500 nM, Selleck Chemicals, Houston, TX, 
USA) and Quercetin (50 µM, Sigma Aldrich) or respective DMSO control for 48 h in sterile 
cultivation medium containing 0.1% FCS. RNA was isolated and fibrotic gene expression 
was measured by qRT-PCR. Supernatants were collected, centrifuged at 14000 g for 10 min 
and stored at -80°C before analysis. 
Western blotting 
Cells or pulverized lung tissue were lysed with Tissue Protein Extraction Reagent (T-Per, 
Thermo Fisher) containing phosphatase and protease inhibitors (Roche Diagnostics, 
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Mannheim, Germany). Protein concentration was determined by BCA assay (Pierce, Thermo 
Fisher Scientific). Equal amounts of protein were loaded with 4× Laemmli loading buffer (150 
mM Tris HCl [pH 6.8], 275 mM SDS, 400 nM dithiothreitol, 3.5% (w/v) glycerol, 0.02% 
bromophenol blue) and subjected to electrophoresis in 17% polyacrylamide gels and 
transferred to PVDF membranes. Supernatants from treated 3D-LTCs were collected and 
stored at -80°C. Samples were normalized to supernatant volume. 200 µL of supernatant 
from each sample was concentrated using Nanosep 10K OMEGA columns (Pall Corporation; 
Ann Arbor, MI, USA) at 15000 g for 20 min. Formed concentrate was diluted in 60 µL lysis 
buffer to form a 3:10 ratio. Western blotting was performed with 6% TRIS-based gels. 
Membranes were blocked with 5% non-fat dried milk solution in TRIS-buffered saline 
containing 0.01% (v/v) Tween (TBS-T) (Applichem) for 1h and incubated with primary 
-actin, A3854, 
Sigma Aldrich, anti proSP-C, ab40879, Abcam (Cambridge, UK), anti E-Cadherin BD 
610181, anti Collagen1, 600-401-103, Rockland (Limerick, PA, USA) at 4°C overnight. Next, 
blots were incubated for 1 h at RT with secondary, HRP-conjugated, antibodies (GE-
Healthcare) prior to visualization of the bands using chemiluminescence reagents (Pierce 
ECL, Thermo Scientific, Ulm, Germany), recording with ChemiDocTMXRS+ system and 
analysis using Image Lab 5.0 software (Biorad, Munich, Germany).  
For analysis of protein expression, peripheral lung tissue samples from the lower lobe, from 
the subpleural region of the lung was used. Lung homogenates were prepared of shock-
frozen lung tissue samples (size 1 cm3) from IPF patients (N=16; mean age  SD: 50.67  
12.010 years; 2 females, 14 males) and non-diseased control subjects (organ donors, N=11; 
mean age  SD: 49.67  7.615 years; 5 females, 5 males, 1 unknown) according to the 
protocol previously described [5]. The protein concentration in lung homogenates was 
determined according to the Pierce® BCA protein assay from Thermo Scientific. 
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For one-dimensional SDS-PAGE, lung homogenates were then diluted (1:3) in 4 SDS-
sample buffer [leading to a final concentration 2% (w/v) SDS, 2.5% (v/v) -mercaptoethanol, 
10% (v/v) glycerol, 12.5 mmol/L tris-HCl [pH 6.8], 0.1% (w/v) bromophenol blue in samples] 
and heated for denaturation at 99°C for 15 min. Denaturated proteins from each sample (50 
g/lane) were then separated by 15% Laemmli-SDS-PAGE. Thereafter, the separated 
proteins were transferred to a PVDF membrane (Millipore) in a semi-dry blotting chamber 
according to the manufacturer´s protocol (Bio-Rad, Munich, Germany). Obtained 
immunoblots were then blocked by incubating at room temperature for 1 h in blocking buffer 
[1 × tris-buffered saline (TBS; 50 mmol/L tris-HCl, pH 7.5, 50 mmol/L NaCl) containing 5% 
(w/v) nonfat dried milk and 0.1 % (w/v) tween 20], followed by immunostaining for p16 
(ab108349, abcam, diluted 1:250) or p21 (ab109520, abcam, diluted 1:500). Blots were 
incubated with primary antibody (diluted in blocking buffer) overnight at 4°C with gentle 
shaking. The blots were then washed four times in 1 × TBS containing 0.1 % (w/v) tween 20, 
and incubated with horseradish peroxidase-conjugated secondary swine anti-rabbit IgG 
(DakoCytomation, Hamburg, Germany; diluted 1:2000 in blocking buffer) for 2 h at rt. After 
four washes, blot membranes were developed with the Immobilon Western 
Chemiluminescent HRP substrate (Millipore), and emitted signals were detected with a 
chemiluminescence imager (Intas ChemoStar, Intas, Göttingen, Germany). Thereafter, blots 
were stripped using stripping buffer  [2% (w/v) SDS and 50 mmol/L dithiothreitol in tris-
buffered saline (TBS)] under gentle shaking at 55°C for 30 min, followed by reprobing the 
blots using antibodies against the loading control protein -actin (ab8226, abcam, diluted 
1:3000). 
For quantification, band intensities in acquired TIFF-images were analyzed by densitometric 
scanning and quantified using ImageJ software (Version 1.46r, NIH). The band densities 
-actin. 
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ELISA 
Supernatants were obtained from assays of primary mouse ATII cells or mouse 3D-LTCs, 
centrifuged at 14000g for 10 min and only cell-free supernatant was used for the assay. 
Samples were then transferred to the respective ELISA plate and the assays were performed 
 DY1627, R&D, Minneapolis, 
Minnesota, USA; IL6  DY406, R&D, Minneapolis, Minnesota, USA, SP-C - CSB-E12639m; 
Cusabio, Washington D.C., Columbia, USA). 
Immunohistochemistry (IHC)  
ZytoChem-Plus AP Kit (Fast Red) (Zytomed Systems, Berlin, Germany) was used for 
immunohistochemical localization of P16, P21, proSP-C, cytokeratin-5 (KRT5) and -SMA in 
formalin-fixed, paraffin-embedded lung tissue sections from patients with sporadic IPF 
(N=14) and organ donors (N=5), according to the manufacturer´s instructions and previous 
published work [6]. Human lungs were placed in 4% (w/v) paraformaldehyde after 
explantation (fixation was done for 12 24h), and processed for paraffin embedding. Sections 
(3 µm) were cut and mounted on positively charged glass slides (Super Frost Plus, 
Langenbrinck (Emmendingen, Germany)). Paraffin-embedded tissue sections of normal 
donor and IPF lungs were deparaffinized in xylene and rehydrated in graded alcohol. 
Antigens were retrieved by cooking the sections for 5 min in 10 mmol/L citrate buffer (pH 6.0) 
using microwave irradiation (800 W). Thereafter, sections cooled down for 20 min at RT, 
followed by repeated cooking (800 W, 5 min) and cooling (20 min at RT). This procedure was 
performed three times. Importantly, the citrate buffer was freshly prepared by mixing 18 mL 
100mmol/L citric acid monohydrate and 82 mL 100mmol/L sodium citrate tribasic dihydrate 
with 900 mL distilled water. 
For immunostaining, the streptavidin-biotin-alkaline phosphatase (AP) method with use of the 
ZytoChem-Plus AP Kit (Fast Red) [Zytomed Systems, Berlin, Germany], according to the 
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manufacturer´s protocol, was employed. In the following, the primary antibodies used for IHC 
are listed, including the sources and dilutions: rabbit polyclonal for human proSP-C (1:750, 
Millipore, AB3786), rabbit monoclonal for human cytokeratin-5 [KRT5] (1:200, Abcam, 
ab75869), rabbit monoclonal for human cytokeratin-7 [KRT7] (1:200, used from Epitomics, 
2303-1 as well as from Abcam, ab68459), rabbit polyclonal for human smooth muscle actin 
[ -SMA] (1:100, Abcam, ab5694), rabbit monoclonal for human p16INK4a (1:75, Abcam, 
ab108349), rabbit monoclonal for human p21 (1:100, Abcam, ab109520) and rabbit 
monoclonal for gamma H2A.X (phospho-S139) (1:100, Abcam, ab81299). 
In general, sections were incubated for 2h at RT with primary antibodies, which were diluted 
in PBS containing 2% (w/v) BSA. Control sections were treated with PBS-2%BSA alone to 
determine the specificity of the staining. Detection was performed with a polyvalent 
secondary biotinylated antibody (rabbit, mouse, rat, guinea pig, provided by the ZytoChem-
Plus AP Kit, 20 min incubation) followed by incubation with AP-conjugated streptavidin (20 
min). Sections were then developed with Fast Red substrate solution, and the reaction was 
terminated by washing in distilled water. The stained sections were counterstained with 
hemalaun (Mayers hemalaun solution, WALDECK Division CHROMA GmbH & CO KG, 
Münster, Germany) and mounted in Glycergel (DakoCytomation). Lung tissue sections were 
scanned with a scanning device (Nano-Zoomer, Hamamatsu), and examined 
histopathologically using the ´NDP.view2 software´ at 100×, 200×, 400× and 800× original 
magnification. IHC for mentioned antibodies was undertaken in 14 IPF- and 5 control-donor 
lung samples. 
Gene set enrichment analysis (GSEA) 
Gene set enrichment analysis (GSEA) for senescence was performed using the GSEA 
Desktop Application software package from the Broad Institute [7] on previously published 
microarrays for whole mouse lungs of PBS- or bleomycin-treated animals (GSE16846) [8], 
fibroblasts isolated from PBS- or bleomycin-treated animals (GSE42564) [9] or isolated ATII 
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cells [1]. GSEA allows for computationally testing whether a defined set of genes, such as a 
list of genes associated with senescence, are significantly enriched in one of two biological 
conditions. Pre-ranked gene lists were generated from normalized data for the ATII cells 
based on log2 fold change whereas fold change was used for generating the fibroblast pre-
ranked list. For whole lung homogenates, genes were ranked using the built-in Signal2Noise 
function. The senescence list was obtained from Fridman et al. [10]. 
Correlation analysis 
Data for the analysis were extracted from Lung Genomics Research Consortium (GSE47460 
GPL4680) and correlated to diffusion capacity of the lung for carbon monoxide (%DLCO) and 
the forced vital capacity (FVC) in human patients as a measure of disease severity. Only 
normal control patients and patients with confirmed IPF were used from the dataset. For 
expression analysis of P16 or P21, the expression data was extracted from the published 
datasets.  
 
Immunofluorescence staining 
For immunofluorescence staining experiments, ATII cells were seeded on poly-l-lysin treated 
coverslips. Cells were stopped at day 2 or after 48 h of treatment with senolytic drugs and 
fixed with ice-cold acetone-methanol (1:1) for 10 min and washed 3 times with 0.1% BSA in 
PBS. Next, cells were permeabilized with 0.1% Triton X-100 solution in PBS for 20 min, 
blocked with 5% BSA in PBS for 30 min at room temperature and incubated with primary 
antibodies (proSP-C 1:100 (AB3786, Millipore, Darmstadt, Germany), E-Cadherin 1:200 
(610181, BD, Franklin Lakes, NJ, USA), Cytokeratin 1:500 (Dako, Glostrup, Denmark), 
Cleaved caspase 3 1:150 (9661, Cell Signaling, Danvers, Massachusetts, USA), Histone 
H3K9me3 1:500 (8898, Abcam, Cambridge, MA 02139, USA), ZO-1 1:200 (400-2200, 
Invitrogen, Waltham, Massachusetts, USA), SMA 1:500 (AB5228, Sigma Aldrich, St. Louis, 
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Missouri USA), followed by secondary antibodies, 1 h each. DAPI (Roche, Basel, 
Switzerland) staining for 10 min was used to visualize cell nuclei. Next, coverslips were fixed 
with 4% PFA for 10 min, mounted with fluorescent mounting medium (Dako, Glostrup, 
Denmark) and visualized with an Axio Imager microscope (Zeiss, Oberkochen, Germany) or 
confocal microscope (LSM 710; Zeiss, Oberkochen, Germany). 
3D-LTCs were fixed with the mixture of acetone-methanol (1:1) for 20 min and punched to a 
4 mm diameter. Tissue was blocked for 1h with 5% BSA in PBS and incubated overnight with 
primary antibodies in 4°C, followed by incubation with appropriate secondary antibodies for 
1h and with DAPI for 5 min. Then tissue was fixed for 30 min with 4% PFA. Staining was 
evaluated via confocal microscopy (LSM 710; Zeiss, Oberkochen, Germany).  
Secretome analysis 
Eight- to ten-week-old, pathogen-free female C57BL/6N mice (Charles River Laboratories, 
Sulzfeld, Germany) were used for the isolation of pmATII cells for secretome analysis. Lung 
fibrosis was induced in the animals by intratracheal instillation of a single dose of bleomycin 
(5 U/kg body weight), dissolved in 80 µl sterile phosphate-buffered saline (PBS). Control 
mice were treated with 80 µl PBS. Mice were sacrificed at day 14 after instillation and 3 mice 
per treatment were pooled for the isolation of pmATII cells. ATII cells were seeded in 12-well 
plates in DMEM media without phenol red and conditioned media (4, 6, and 8 h, respectively) 
were harvested either on the first day of culture or after 2 days of culture. (day 2 4 h; day 2 6 
h; day 2 8 h; Bleo ATII: n=3; PBS ATII: n=2). Samples were snap frozen in liquid nitrogen 
and subjected to mass spectrometry analysis as previously described [11]. Briefly, proteins in 
conditioned media were digested in solution with trypsin and LysC into peptides, which were 
analyzed on a Q-Exactive mass spectrometer (Thermo Fischer). Mass spec raw data was 
processed using the MaxQuant software [12] and proteins were quantified using the 
embedded label free quantification algorithm MaxLFQ [13]. Statistical data analysis was 
performed using the Perseus software suite [14]. 
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Flow cytometry (FCM)-based apoptosis assay in pmATII cells  
FCM-
instructions (Annexin V apoptosis kit, eBioscience, San Diego, CA). Briefly, pmATII cells from 
PBS- and bleomycin-treated animals (day 2) were incubated with vehicle (DMSO) or 
senolytic drugs Dasatinib (500 nM, Selleck Chemicals, Houston, TX, USA) and Quercetin (50 
µM, Sigma Aldrich, St Louis, MA, USA) for 48 hours and were subsequently incubated with 
Bafilomycin A1 (100 nM, Enzo Life Sciences, Farmingdale, NY; USA) and C12FDG (20 nM, 
Life technologies, Carlsbad, CA; USA) for 1 and 2 h, respectively. The cells were harvested 
with trypsin/EDTA (Life technologies), washed once with calcium chloride-free and 
magnesium chloride-free PBS (Life technologies), and once with the Annexin V-binding 
buffer (eBioscience). Cells were incubated with APC-conjugated Annexin V (eBioscience) for 
15 min, washed, and resuspended in the binding buffer. Cells without C12FDG treatment 
were further stained with propidium iodide solution (PI, eBioscience). The groups of the cells 
stained with Annexin V+PI or Annexin V+C12FDG were analyzed with a FACS LSRII cell 
analyzer (BD Bioscience). 
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Supplemental Figures 
Figure S1: Expression of senescence markers is upregulated in IPF patients. 
Gene expression of P16 and P21 in IPF versus donor specimens. N=91 donor, N=122 IPF. 
Data extracted from the LGRC GSE47460 GPL4680. Data is presented as mean ± s.e.m.. 
Means were compared using Mann-Whitney U test. (B) Correlation between P16 expression 
in the lung and the lung function parameter %predicted DLCO (N=194) showed a significantly 
negative linear correlation (dashed line = 95% CI; data extracted from LGRC GSE47460 
GPL4680). 
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Figure S2: Expression and localization of P16 and P21 in IPF lungs. 
(A, B) Immunohistochemical staining of serial sections of IPF lung tissue for -SMA (marker 
for myofibroblasts/mesenchymal cells), proSP-C (marker for alveolar epithelial type II [ATII] 
cells), cytokeratin 5 (KRT5, marker for bronchiolar basal cells), cytokeratin 7 (KRT7, marker 
for simple epithelia) and P16 protein. KRT5+ KRT7+ basal cells expressing P16 are indicated 
by asterisks; -SMA expressing mesenchymal cells which revealed no pronounced 
expression for P16 are indicated by hashmarks; proSP-C+ KRT7+ positive ATII cells 
expressing P16 (B) are indicated by arrows; proSP-C- KRT5- KRT7+ epithelial cells 
expressing P16 are indicated by arrowheads; proSP-C+ KRT5+ KRT7+ positive epithelial cells 
are indicated by dashed arrows. The lung region shown in (A) did not exhibit ATII cells. The 
lung region shown in the left panel of (B) exhibited aberrant epithelial structures indicating 
KRT5 expressing basal cells (with abnormal superficial localization) in close proximity to 
proSP-C expressing ATII cells, as well as abnormal epithelial cells with co-expression of 
KRT5 and proSP-C, which all expressed P16. In contrast, the alveolar airspace shown in the 
middle panel of (B) indicated only a sparse amount of P16 expressing ATII. (C, D) 
Immunohistochemical staining of serial sections of IPF lung tissue for -SMA (marker for 
myofibroblasts/mesenchymal cells), proSP-C (marker for alveolar epithelial type II [ATII] 
cells), cytokeratin 5 (KRT5, marker for bronchiolar basal cells), cytokeratin 7 (KRT7, marker 
for simple epithelia) and P21 protein. KRT5+ KRT7+ positive basal cells expressing P21 (C) 
are indicated by asterisks; -SMA expressing mesenchymal cells which revealed no 
pronounced expression for P21 are indicated by hashmarks; proSP-C+ KRT7+ positive ATII 
cells expressing P21 are indicated by arrows; proSP-C- KRT5- KRT7+ epithelial cells 
expressing P21 (C) are indicated by arrowheads. The lung region shown in (C) exhibited 
aberrant epithelial structures indicating KRT5 expressing bronchiolar basal cells in close 
proximity to proSP-C expressing ATII cells, as well as epithelial cells with co-expression of 
KRT5 and proSP-C. 
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Figure S3: Induction and upregulation of H2A.X (phospho-S139) in epithelial cells of 
IPF lungs. 
(A-E) Immunohistochemical staining of serial sections of IPF (A, B, D, E) or donor lung 
tissue (C) for proSP-C (marker for alveolar epithelial type II [ATII] cells), cytokeratin 5 (KRT5, 
marker for bronchiolar basal cells), cytokeratin 7 (KRT7, marker for simple epithelia) and 
senescence markers H2A.X (p-S139) and P16. In IPF (A, B, E), proSP-C+ KRT7+ ATII cells 
indicated robust nuclear staining for H2A.X (p-S139) which co-localized with P16 
overexpression (indicated by arrows). The same observations were made in proSP-C- KRT5- 
KRT7+ epithelial cells of alveolar spaces (indicated by arrowheads), whereas no substantial 
immunostaining could be observed in the fibrotic interstitium in IPF lungs (C). 
The IPF-lung regions shown in B, D and E exhibited aberrant epithelial structures indicating 
KRT5 expressing basal cells (with abnormal superficial localization) in close proximity to 
proSP-C expressing ATII cells, which also revealed in part H2A.X (p-S139) expression in 
co-localization with P16 (indicated by asterisks). In addition, proSP-C+ KRT5+ KRT7+ positive 
epithelial cells in areas of aberrant re-epithelialization (E) indicated also concomitant 
expression of H2A.X and P16 (indicated by dashed arrows). In general, induction of nuclear 
H2A.X (p-S139) or P16 expression was frequently observed in bronchiolar basal cells in 
areas of bronchiolization in IPF (B, D, E), but also in normal bronchioles of IPF lungs (not 
shown). In some instances, P16 overexpressing bronchiolar basal cells in IPF lungs did not 
indicate pronounced co-expression of H2A.X (p-S139) (right panel of B, left panel of D). 
This phenomenon was also in part observed in proSP-C+ KRT7+ ATII cells as well as in other 
described epithelial cells (not shown). In age-matched normal donor lungs (C), minimal 
staining for P16 was observed; and no pronounced immunostaining for H2A.X (p-S139) 
could be detected in any cells of donor lungs. 
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Figure S4: Senescent phenotype of ATII cells after bleomycin challenge. (A) Data for 
P16 and P21 was extracted from GSE40151 [15] for PBS/bleomycin timecourse. (B) Mice 
were instilled with PBS or Bleomycin. At day 14 after instillation mice were sacrificed and 
pmATII cells were isolated. Cells were stained for EpCAM, CD45 and CD31 and analyzed by 
FACS. Shown are mean ± s.e.m., n=3-6. (C) Representative images of immunofluorescence 
staining for senescence associated heterochromatic foci marker H3K9me3 and epithelial cell 
marker E-Cadherin in fibrotic and non-fibrotic pmATII cells at day 2 of culture. Fluorescent 
images represent a 630× magnification. Scale bar represents 20 µm. Representative of n=2. 
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Figure S5: Depletion of senescent cells in fibrotic pmATII cells  
Mice were instilled with either PBS or bleomycin (Bleo). At day 14 after instillation mice were 
sacrificed and pmATII cells were isolated. (A) Gene expression analysis of fibrotic markers 
after 24/48 h of mock treatment was performed by qPCR. Data were normalized to Hprt
is presented as mean ± s.e.m.. Significance was assessed with one-way Anova followed by 
Newman- (B-D) Fibrotic pmATII cells were cultured in 
the presence of senolytic drugs Dasatinib (D; 200 nM) and Quercetin (Q; 50 µM). After 24 
hours, expression of (B) P16 (C) fibrotic markers and (D) epithelial cell markers was 
analyzed by qPCR. Data were normalized to Hprt mean ± s.e.m.. 
-test, n=4. Significance: *p<0.05, **p<0.01; 
***p<0.001. 
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Figure S6: Depletion of senescent cells in non-fibrotic pmATII cells  
Mice were instilled with PBS. At day 14 after instillation mice were sacrificed and pmATII 
cells were isolated. Non-fibrotic pmATII cells were cultured for 48 h in the presence of 
senolytic drugs Dasatinib (D; 200 nM) and Quercetin (Q; 50 µM) and assessed for (A) cell 
numbers. Data are presented as normalized to DMSO control and as mean ± s.e.m. 
-test, n=3. (B) P16 expression. Data were 
normalized to Hprt mean ± s.e.m, Significance was assessed with 
-test, n=6. (C) Representative images of immunofluorescence staining for 
the apoptotic marker cleaved caspase 3 and E-Cadherin. Fluorescent images represent a 
630× magnification. The scale bar represents 20 µm. (D-F) qPCR analysis of non-fibrotic 
pmATII cells treated with senolytic drugs for the expression of (D) SASP markers, (E) fibrotic 
markers, (F) epithelial cell markers. Data were normalized to Hprt 
mean ± s.e.m. -test, n=6. *p<0.05, 
***p<0.001. 
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Figure S7: Characterization of fibrotic markers in PBS/Bleo 3D-LTCs.  
Mice were instilled with either PBS or bleomycin. At day 14 after instillation mice were 
sacrificed and 3D-LTCs were generated. (A) Gene expression of fibrotic markers of 3D-LTCs 
after 48 h of culture was analyzed by qPCR. Data were normalized to Hprt
as mean ± s.e.m.. Significance was assessed wit -test, n=8.  
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Figure S8: Depletion of senescent cells in non-fibrotic 3D-LTCs.  
Mice were instilled with PBS. At day 14 after instillation mice were sacrificed and 3D-LTCs 
were generated. 3D-LTCs were cultured for 48 h in the presence of senolytic drugs Dasatinib 
(D; 200 nM) and Quercetin (Q; 50 µM). (A) Representative images of immunofluorescence 
staining for apoptotic marker cleaved caspase 3. Fluorescent images represent a 200× 
magnification. The scale bar represents 50 µm. (B-D) 3D-LTCs from PBS animals treated 
with senolytic drugs were analyzed by qPCR for (B) components of the SASP (C) fibrotic 
markers (D) or Sftpc. Data were normalized to Hprt mean ± s.e.m.. 
t-test, n=6. (E) ProSP-C expression was 
assessed by Immunoblot. -Actin was used as a loading control. Quantification of proSP-C 
protein relative to -Actin. n=3. (F) Secreted Collagen I was assessed by Immunoblot. 
Quantification of secreted Collagen I normalized to supernatant volume. Significance was 
-test.n=3. Significance: *p<0.05, **p<0.01; ***p<0.001. 
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